// App-Quantinova.ai

: Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF)

Researchers

Presenter

  • Athol Wells

Principal Investigators

  • Jrgen Behr

  • Wibke Stansen

  • Susanne Stowasser

  • Toby M. Maher

Medical Centers

  • National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and the National Heart and Lung Institute, Imperial College, London, United Kingdom,

  • Medizinische Klinik und Poliklinik V, University of Munich, LMU and Asklepios Klinik München-Gauting, Member of the German Center for Lung Research, Munich, Germany,

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim Am Rhein, Germany

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved